Novo Nordisk webmaster@novonordisk.com http://video.novonordisk.com/tag/Insulin en-us Visualplatform http://blogs.law.harvard.edu/tech/rss Novo Nordisk no http://video.novonordisk.com/photo/7772789 <p>This film depicts some of the defining moments that have shaped Novo Nordisk during its 90 years of history to become who we are today.<br> It describes the journey to change diabetes that started with the first insulin production in the 1920-ies and which will soon be facing a global challenge of half a billion people with diabetes.<br> The film has been produced to commemorate the first Novo Nordisk insulin that was brought to the market 90 years ago.</p><p><a href="http://video.novonordisk.com/photo/7772789"><img src="http://video.novonordisk.com/7718125/7772789/4ecce2e7555b1cec3895ed5ccea2c7dc/standard" width="600" height="338"/></a></p> http://video.novonordisk.com/photo/7772789 Mon, 04 Mar 2013 10:02:07 GMT Novo Nordisk 90th Anniversary: Defining moments This film depicts some of the defining moments that have shaped Novo Nordisk during its 90 years of history to become who we are today. It describes the journey to change diabetes that started with the first insulin production in the 1920-ies and which will soon be facing a global challenge of half a billion people with diabetes. The film has been produced to commemorate the first Novo Nordisk insulin that was brought to the market 90 years ago. This film depicts some of the defining moments that have shaped Novo Nordisk during its 90 years of history to become who we are today. It describes the journey to change diabetes that started with the first insulin production in the 1920-ies and which will soon be facing a global challenge of half a billion people with diabetes. The film has been produced to commemorate the first Novo Nordisk insulin that was brought to the market 90 years ago. Novo Nordisk 11:20 <p>This film depicts some of the defining moments that have shaped Novo Nordisk during its 90 years of history to become who we are today.<br> It describes the journey to change diabetes that started with the first insulin production in the 1920-ies and which will soon be facing a global challenge of half a billion people with diabetes.<br> The film has been produced to commemorate the first Novo Nordisk insulin that was brought to the market 90 years ago.</p><p><a href="http://video.novonordisk.com/photo/7772789"><img src="http://video.novonordisk.com/7718125/7772789/4ecce2e7555b1cec3895ed5ccea2c7dc/standard" width="600" height="338"/></a></p> 90 90th anniversary changing defining diabetes haemophilia hemophilia history insulin moments nordisk novo http://video.novonordisk.com/photo/6473164 <p>The lead designer behind the NovoPen® 5, Ramin Nateghi-Elahi, Novo Nordisk, explains the aim to heighten the safety of insulin treatment by integrating a memory function into the injection pen that reminds the patient whether a dose has been taken or not. This helps the patient to avoid missing an injection leading to uncontrolled blood sugar levels or overdosing insulin, which may have severe consequences.</p><p><a href="http://video.novonordisk.com/photo/6473164"><img src="http://video.novonordisk.com/4959050/6473164/9cebaf153f0b2c3278ff70155a72c480/standard" width="600" height="338"/></a></p> http://video.novonordisk.com/photo/6473164 Mon, 02 Jul 2012 09:00:00 GMT Interview with the lead designer behind NovoPen(r) 5, Ramin Nateghi-Elahi The lead designer behind the NovoPen® 5, Ramin Nateghi-Elahi, Novo Nordisk, explains the aim to heighten the safety of insulin treatment by integrating a memory function into the injection pen that reminds the patient whether a dose has been taken or not. This helps the patient to avoid missing an injection leading to uncontrolled blood sugar levels or overdosing insulin, which may have severe consequences. The lead designer behind the NovoPen® 5, Ramin Nateghi-Elahi, Novo Nordisk, explains the aim to heighten the safety of insulin treatment by integrating a memory function into the injection pen that reminds the patient whether a dose has been taken or not. This helps the patient to avoid missing an injection leading to uncontrolled blood sugar levels or overdosing insulin, which may have severe consequences. Novo Nordisk 00:49 <p>The lead designer behind the NovoPen® 5, Ramin Nateghi-Elahi, Novo Nordisk, explains the aim to heighten the safety of insulin treatment by integrating a memory function into the injection pen that reminds the patient whether a dose has been taken or not. This helps the patient to avoid missing an injection leading to uncontrolled blood sugar levels or overdosing insulin, which may have severe consequences.</p><p><a href="http://video.novonordisk.com/photo/6473164"><img src="http://video.novonordisk.com/4959050/6473164/9cebaf153f0b2c3278ff70155a72c480/standard" width="600" height="338"/></a></p> (r) 5 Award Design Dot Nordisk Novo NovoPen R&D Red and device function injection insulin medical memory patient pen safety security http://video.novonordisk.com/photo/6463590 <p>Scientific Director of Diabetes Biology, Erica Nishimura, shows us how she takes ‘little steps every day…’ towards the next scientific breakthrough in diabetes care. For Erica, it is the brainstorming in multi-disciplinary teams and reaching out to external experts in the field that gives her the insight she needs to move her research closer to the goal of finding the ultimate therapeutic insulin that only lowers blood glucose when necessary.</p><p><a href="http://video.novonordisk.com/photo/6463590"><img src="http://video.novonordisk.com/4959050/6463590/f030c28b0fda59fd7bae2529f25eb87f/standard" width="600" height="338"/></a></p> http://video.novonordisk.com/photo/6463590 Mon, 25 Jun 2012 12:20:13 GMT Searching for the 'holy grail' in insulin treatment Scientific Director of Diabetes Biology, Erica Nishimura, shows us how she takes ‘little steps every day…’ towards the next scientific breakthrough in diabetes care. For Erica, it is the brainstorming in multi-disciplinary teams and reaching out to external experts in the field that gives her the insight she needs to move her research closer to the goal of finding the ultimate therapeutic insulin that only lowers blood glucose when necessary. Scientific Director of Diabetes Biology, Erica Nishimura, shows us how she takes ‘little steps every day…’ towards the next scientific breakthrough in diabetes care. For Erica, it is the brainstorming in multi-disciplinary teams and reaching out to external experts in the field that gives her the insight she needs to move her research closer to the goal of finding the ultimate therapeutic insulin that only lowers blood glucose when necessary. Novo Nordisk 02:28 <p>Scientific Director of Diabetes Biology, Erica Nishimura, shows us how she takes ‘little steps every day…’ towards the next scientific breakthrough in diabetes care. For Erica, it is the brainstorming in multi-disciplinary teams and reaching out to external experts in the field that gives her the insight she needs to move her research closer to the goal of finding the ultimate therapeutic insulin that only lowers blood glucose when necessary.</p><p><a href="http://video.novonordisk.com/photo/6463590"><img src="http://video.novonordisk.com/4959050/6463590/f030c28b0fda59fd7bae2529f25eb87f/standard" width="600" height="338"/></a></p> Collaboration Diabetes Diabetes Biology Discovery Innovation Insulin Knowledge Science Treatment http://video.novonordisk.com/photo/4976495 <p>Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, discusses how innovation drives our portfolio. A unique combination of chemical and protein engineering competencies allows our scientists to design new treatments that address the unmet needs of people living with chronic diseases like diabetes, haemophilia and autoimmune inflammatory diseases.</p><p><a href="http://video.novonordisk.com/photo/4976495"><img src="http://video.novonordisk.com/4959050/4976495/a2430f7164ae1ef41f7ccba879e16741/standard" width="600" height="338"/></a></p> http://video.novonordisk.com/photo/4976495 Mon, 07 May 2012 11:01:57 GMT Our portfolio Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, discusses how innovation drives our portfolio. A unique combination of chemical and protein engineering competencies allows our scientists to design new treatments that address the unmet needs of people living with chronic diseases like diabetes, haemophilia and autoimmune inflammatory diseases. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, discusses how innovation drives our portfolio. A unique combination of chemical and protein engineering competencies allows our scientists to design new treatments that address the unmet needs of people living with chronic diseases like diabetes, haemophilia and autoimmune inflammatory diseases. Novo Nordisk 03:27 <p>Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, discusses how innovation drives our portfolio. A unique combination of chemical and protein engineering competencies allows our scientists to design new treatments that address the unmet needs of people living with chronic diseases like diabetes, haemophilia and autoimmune inflammatory diseases.</p><p><a href="http://video.novonordisk.com/photo/4976495"><img src="http://video.novonordisk.com/4959050/4976495/a2430f7164ae1ef41f7ccba879e16741/standard" width="600" height="338"/></a></p> CSO Krogsgaard MKT Mads Thomsen academic action biotech chemical competencies curves design development drug engineering innovation insulin need oral partnering profiles protein therapeutic unmet http://video.novonordisk.com/photo/4872851 <p>12 April Novo Nordisk officially launched a programme to make insulin and diabetes care more accessible to poor populations. In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients’ homes.</p><p><a href="http://video.novonordisk.com/photo/4872851"><img src="http://video.novonordisk.com/4465641/4872851/7bd5137b69220fc4129c4bf0c27bb103/standard" width="600" height="338"/></a></p> http://video.novonordisk.com/photo/4872851 Mon, 16 Apr 2012 07:14:46 GMT In Kenya, Novo Nordisk tests a new business model to improve access to insulin 12 April Novo Nordisk officially launched a programme to make insulin and diabetes care more accessible to poor populations. In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients’ homes. 12 April Novo Nordisk officially launched a programme to make insulin and diabetes care more accessible to poor populations. In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients’ homes. Novo Nordisk 05:05 <p>12 April Novo Nordisk officially launched a programme to make insulin and diabetes care more accessible to poor populations. In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients’ homes.</p><p><a href="http://video.novonordisk.com/photo/4872851"><img src="http://video.novonordisk.com/4465641/4872851/7bd5137b69220fc4129c4bf0c27bb103/standard" width="600" height="338"/></a></p> Access Bottom Insulin Kenya Pyramid accessible affordable of the to http://video.novonordisk.com/photo/4736169 <p>A corporate presentation film produced in 1942. Danish narration. Black and white film.</p> <p style="margin-bottom: 0px;">The title in English is: Insulin - A Film About Science's Victory over Illnes and Death.</p><p><a href="http://video.novonordisk.com/photo/4736169"><img src="http://video.novonordisk.com/4465660/4736169/d7e35051a68e1a429cfc921b93c6fcb4/standard" width="600" height="450"/></a></p> http://video.novonordisk.com/photo/4736169 Tue, 27 Mar 2012 12:18:53 GMT Insulin - En film om videnskabens sejr og sygdom og død - 1942 A corporate presentation film produced in 1942. Danish narration. Black and white film. The title in English is: Insulin - A Film About Science's Victory over Illnes and Death. A corporate presentation film produced in 1942. Danish narration. Black and white film. The title in English is: Insulin - A Film About Science's Victory over Illnes and Death. Novo Nordisk 23:24 <p>A corporate presentation film produced in 1942. Danish narration. Black and white film.</p> <p style="margin-bottom: 0px;">The title in English is: Insulin - A Film About Science's Victory over Illnes and Death.</p><p><a href="http://video.novonordisk.com/photo/4736169"><img src="http://video.novonordisk.com/4465660/4736169/d7e35051a68e1a429cfc921b93c6fcb4/standard" width="600" height="450"/></a></p> 1942 corporate documentary history image insulin laboratorium nordisk novo http://video.novonordisk.com/photo/4736263 <p>A corporate presentation film produced in 1932.<br /> Silent movie with German text screens.</p><p><a href="http://video.novonordisk.com/photo/4736263"><img src="http://video.novonordisk.com/4465686/4736263/3b3a6cec6ed8e62a8a47052a09dac2f3/standard" width="600" height="450"/></a></p> http://video.novonordisk.com/photo/4736263 Tue, 27 Mar 2012 11:57:20 GMT Nordisk Insulin-Laboratorium - Silent Movie 1932 A corporate presentation film produced in 1932. Silent movie with German text screens. A corporate presentation film produced in 1932. Silent movie with German text screens. Novo Nordisk 16:08 <p>A corporate presentation film produced in 1932.<br /> Silent movie with German text screens.</p><p><a href="http://video.novonordisk.com/photo/4736263"><img src="http://video.novonordisk.com/4465686/4736263/3b3a6cec6ed8e62a8a47052a09dac2f3/standard" width="600" height="450"/></a></p> 1932 corporate documentary history image insulin laboratorium nordisk novo http://video.novonordisk.com/photo/4102421 <p>Peter Kurtzhals explains about the different types of diabetes and what kind of medicine the different patients can use. We hear about how people with diabetes have to try to control their blood sugar levels. It is difficult for patients to get started on injecting themselves with insulin, as they currently have to. Therefore an insulin tablet would be a big help for the patients. Peter Kurtzhals explains what is being done to develop such a tablet and what the challenges are.</p><p><a href="http://video.novonordisk.com/photo/4102421"><img src="http://video.novonordisk.com/1984079/4102421/981f6005ef31469e649fd8ba08570a15/standard" width="600" height="338"/></a></p> http://video.novonordisk.com/photo/4102421 Fri, 16 Dec 2011 06:00:00 GMT The challenges of developing insulin in a tablet Peter Kurtzhals explains about the different types of diabetes and what kind of medicine the different patients can use. We hear about how people with diabetes have to try to control their blood sugar levels. It is difficult for patients to get started on injecting themselves with insulin, as they currently have to. Therefore an insulin tablet would be a big help for the patients. Peter Kurtzhals explains what is being done to develop such a tablet and what the challenges are. Peter Kurtzhals explains about the different types of diabetes and what kind of medicine the different patients can use. We hear about how people with diabetes have to try to control their blood sugar levels. It is difficult for patients to get started on injecting themselves with insulin, as they currently have to. Therefore an insulin tablet would be a big help for the patients. Peter Kurtzhals explains what is being done to develop such a tablet and what the challenges are. Novo Nordisk 16:34 <p>Peter Kurtzhals explains about the different types of diabetes and what kind of medicine the different patients can use. We hear about how people with diabetes have to try to control their blood sugar levels. It is difficult for patients to get started on injecting themselves with insulin, as they currently have to. Therefore an insulin tablet would be a big help for the patients. Peter Kurtzhals explains what is being done to develop such a tablet and what the challenges are.</p><p><a href="http://video.novonordisk.com/photo/4102421"><img src="http://video.novonordisk.com/1984079/4102421/981f6005ef31469e649fd8ba08570a15/standard" width="600" height="338"/></a></p> R&D blood control insulin oral sugar tablet http://video.novonordisk.com/photo/4102403 <p>The discovery and development of insulin from the early 1920s and up until today. Novo Nordisk’s Chief Science Officer Mads Krogsgaard Thomsen explains about diabetes and the discovery of insulin, the development of insulin and the differences of human insulin, modern insulin and the next generation insulin; about how people with diabetes have to control their blood sugar levels; about how insulin research and development has reduced the number of times people with diabetes have to inject themselves.</p><p><a href="http://video.novonordisk.com/photo/4102403"><img src="http://video.novonordisk.com/1984072/4102403/75cbb324fb972e4f82eedaa29bb460cf/standard" width="600" height="338"/></a></p> http://video.novonordisk.com/photo/4102403 Fri, 16 Dec 2011 06:00:00 GMT The history of insulin The discovery and development of insulin from the early 1920s and up until today. Novo Nordisk’s Chief Science Officer Mads Krogsgaard Thomsen explains about diabetes and the discovery of insulin, the development of insulin and the differences of human insulin, modern insulin and the next generation insulin; about how people with diabetes have to control their blood sugar levels; about how insulin research and development has reduced the number of times people with diabetes have to inject themselves. The discovery and development of insulin from the early 1920s and up until today. Novo Nordisk’s Chief Science Officer Mads Krogsgaard Thomsen explains about diabetes and the discovery of insulin, the development of insulin and the differences of human insulin, modern insulin and the next generation insulin; about how people with diabetes have to control their blood sugar levels; about how insulin research and development has reduced the number of times people with diabetes have to inject themselves. Novo Nordisk 16:51 <p>The discovery and development of insulin from the early 1920s and up until today. Novo Nordisk’s Chief Science Officer Mads Krogsgaard Thomsen explains about diabetes and the discovery of insulin, the development of insulin and the differences of human insulin, modern insulin and the next generation insulin; about how people with diabetes have to control their blood sugar levels; about how insulin research and development has reduced the number of times people with diabetes have to inject themselves.</p><p><a href="http://video.novonordisk.com/photo/4102403"><img src="http://video.novonordisk.com/1984072/4102403/75cbb324fb972e4f82eedaa29bb460cf/standard" width="600" height="338"/></a></p> CSO. Krogsgaard Mads Nordisk Novo Thomsen animal discovery human insulin modern of http://video.novonordisk.com/photo/2182444 <p>Mads Krogsgaard Thomsen, executive vice president and Chief Science Officer at Novo Nordisk, on the umnet need in diabetes treatment.</p><p><a href="http://video.novonordisk.com/photo/2182444"><img src="http://video.novonordisk.com/1984075/2182444/989810d14258f5ca2594156c014c2ad5/standard" width="600" height="338"/></a></p> http://video.novonordisk.com/photo/2182444 Fri, 24 Jun 2011 14:59:15 GMT The unmet need in diabetes treatment Mads Krogsgaard Thomsen, executive vice president and Chief Science Officer at Novo Nordisk, on the umnet need in diabetes treatment. Mads Krogsgaard Thomsen, executive vice president and Chief Science Officer at Novo Nordisk, on the umnet need in diabetes treatment. Novo Nordisk 02:19 <p>Mads Krogsgaard Thomsen, executive vice president and Chief Science Officer at Novo Nordisk, on the umnet need in diabetes treatment.</p><p><a href="http://video.novonordisk.com/photo/2182444"><img src="http://video.novonordisk.com/1984075/2182444/989810d14258f5ca2594156c014c2ad5/standard" width="600" height="338"/></a></p> CSO GLP-1 Nordisk Novo diabetes insulin need treatment unmet